Boudina Maria, Zisimopoulou Eleana, Xirou Persefoni, Chrisoulidou Alexandra
Department of Endocrinology, Theagenio Cancer Hospital, 54639 Thessaloniki, Greece.
Department of Pathology, Genekor S.A., 15344 Gerakas, Greece.
J Clin Med. 2024 Oct 14;13(20):6119. doi: 10.3390/jcm13206119.
Differentiated thyroid cancer (DTC) includes many subtypes, which demonstrate favorable to aggressive behavior. During the past decades, efforts have been made to describe aggressive thyroid cancers. Within DTC, aggressive variants constitute rare entities with unique histopathological features and compromised survival, as local and distant metastatic disease is frequent. In recent years, the distinct category of poorly differentiated thyroid cancer was introduced in 2004 and the type of differentiated high-grade thyroid carcinoma was recently added in the 2022 WHO classification of thyroid neoplasms. Finally, anaplastic thyroid cancer exhibits a rapid, resistant to therapy, progression and confers the shortest survival. In this review, we will present the characteristics of these thyroid cancer types and also discuss the treatment, management, and follow-up of these difficult cases. Emphasis was given to recent bibliography of the last decade.
分化型甲状腺癌(DTC)包括许多亚型,其行为表现从良性到侵袭性不等。在过去几十年中,人们一直在努力描述侵袭性甲状腺癌。在DTC中,侵袭性变体是罕见的实体,具有独特的组织病理学特征且生存率较低,因为局部和远处转移疾病很常见。近年来,2004年引入了低分化甲状腺癌这一独特类别,并且在2022年世界卫生组织甲状腺肿瘤分类中最近增加了高分化型甲状腺癌。最后,未分化甲状腺癌进展迅速、对治疗耐药,生存期最短。在本综述中,我们将介绍这些甲状腺癌类型的特征,并讨论这些疑难病例的治疗、管理和随访。重点关注了过去十年的最新文献。